Aflibercept biosimilar shows efficacy and safety for treating neovascular AMD

• Posted on: Aug 17 2023
• By: Saratoga Opthalmology
• Leave a response

A phase 3 trial reveals similar performance between aflibercept and an aflibercept biosimilar for the treatment of neovascular AMD.
Source: AAO

Posted in: Uncategorized